Human study PLS-00062
Circulating PGC-1α and MOTS-c Peptide as Potential Mitochondrial Biomarkers in Patients Undergoing Aortic Valve Replacement.
Version 1 · published November 7, 2026 · evidence through November 7, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.
Only the abstract was available. Essential methods may be missing, which limits what can be judged.
Reports of this study
Every publication, registration and abstract describing this one study. Participants are counted once.
- Circulating PGC-1α and MOTS-c Peptide as Potential Mitochondrial Biomarkers in Patients Undergoing Aortic Valve Replacement.primary · Biologics : targets & therapy · 2025-03-13 · PMID 40104672 · DOI
Design and participants
- Design
- Cross-sectional study
- Population
- Patients diagnosed with aortic valve disease and scheduled for aortic valve replacement (17), and healthy controls (22).
- Conditions
- Aortic valve disease
- Planned enrollment (registry)
- Not reported
- Enrolled
- Not reported
- Randomized
- Not reported
- Completed follow-up
- Not reported
Intervention and comparator
What each group received. Related peptides, analogs and combinations are never treated as the compound itself.
What the authors reported
As stated in the sources. This is the authors’ account, not Peptide Library’s assessment.
Adverse events
None reported. That is not evidence of safety, and how safety was monitored isn’t described.
The authors concluded (paraphrased): Plasma PGC1α and MOTS-c were lower in aortic valve disease patients than in controls. The authors propose both as potential plasma biomarkers for detecting aortic valve disease, pending studies that include early-stage patients.
Peptide Library’s assessment
An automated assessment, made by AI separately from the authors’ conclusions and not reviewed by a person. How risk of bias is assessed.
Limitations
- other: MOTS-c was measured as an endogenous biomarker and was never administered, so the study gives no information on the effects of MOTS-c treatment.
- small or imprecise: Only 17 patients and 22 healthy controls were recruited, per the abstract.
- abstract only: Only the abstract is available in the record. No numeric results or methodological details are given.
- confounding: Cross-sectional comparison with healthy controls; the abstract does not describe how comorbidities or medications were handled.
No risk-of-bias assessment has been published for this study’s results.
Claims this study informs
- Improves metabolic health: not eligible (not primary study) for “Insulin sensitivity, glucose control or body weight”
- Is safe for human administration: not eligible (not primary study) for “Adverse events, serious adverse events and discontinuations”
Where each value comes from
- author_conclusion: PMID 40104672, abstract (Conclusion, sentences 1-3) · extracted by AI (automated, not verified by a person) · abstract only
- design: PMID 40104672, abstract (Purpose, sentence 5) · extracted by AI (automated, not verified by a person) · abstract only
- outcomes: PMID 40104672, abstract (Patients and methods, sentence 2) · extracted by AI (automated, not verified by a person) · abstract only
- participants: PMID 40104672, abstract (Patients and methods, sentence 1) · extracted by AI (automated, not verified by a person) · abstract only
- population: PMID 40104672, abstract (Patients and methods, sentence 1) · extracted by AI (automated, not verified by a person) · abstract only
Version 1 · published November 7, 2026 · evidence through November 7, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.
These assessments describe published research. Records marked automated were produced by AI under the published methodology and have not been reviewed by a person; they can contain errors. None of this is medical advice, not a statement about any product’s safety for human use, and not a regulatory approval. Peptide Library’s vendor and partner relationships play no part in them (editorial independence).